Board of Directors
Peter Høngaard Andersen
Chairman of the Board, Scandion Oncology and member of Board of Directors since June 2019
Education: Holds degrees in Chemistry, Biochemistry and Medicine
Background: Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and Corporate Patents. Founder of Innovation Fund Denmark and Managing Director until May 2019 Chairing Innovative Medicines Initiative (IMI) from 2009 – 2014. Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.
Other ongoing assignments: Board member in Immunovia AB, Monsenso A/S, Venture Partner in Ysios Capital and member of the Scientific Advisory Board in Eir Ventures.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
62,065 shares and 80,377 warrants
Jørgen Bardenfleth
Vice-Chairman of the Board, Scandion Oncology and member of Board of Directors since 2018
Education: MSc in Engineering from the Technical University of Denmark (DTU) and a MBA from the University of California, Los Angeles
Background: Professional board member since 2013, prior General Manager in high tech companies Microsoft, Intel and Hewlett-Packard 1989-2013. Board and steering committee work in Danish Science Parks, Innovationsfonden and Innovation Technology consortias.
Other ongoing assignments: Chairman of the Board in Lyngsoe Systems, Dubex, Symbion, Medical Technology Innovation Consortium (MTIC), COBIS and Impero. Board member in Bizbrains, Minerva, Accelerace, BLOXHUB (vice chair), CataCap et al.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
425,629 shares and 53,585 warrants (Partly owned via Lioneagle ApS)
Carl Borrebaeck
Member of the Board of Directors since 2017
Education: DSc
Background: Professor Lund University. Co-founder of Immunovia AB, Senzagen AB, BioInvent International AB, Alligator Bioscience AB.
Other ongoing assignments: Chairman of the Board in Immunovia AB, SenzaGen AB and PainDrainer AB. Board member in PainDrainer AB.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
112,165 shares and 26,792 warrants (Partly owned via CB Ocean Capital AB)
Christian Vinding Thomsen
Member of the Board of Directors since 2017
Education: Holds a law degree (Cand.jur.) from the University of Copenhagen’s Faculty of Law
Background: Partner, Attorney-at-law, BKH Law P/S. Previously, Partner, attorney-at-law, Bech-Bruun . Life Science specialist (M&A and regulatory).
Other ongoing assignments: Chairman of the board in KT Stålindustri A/S and vice chairman at Medicoindustriens Udredningspanel. Board member in Reponex Pharmaceuticals A/S, AKI Therapeutics ApS, RepoCeuticals A/S and the Danish Life Science Law Association.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
10,000 shares and 26,792 warrants
Thomas Feldthus
Member of the Board of Directors since 2018
Education: MSc in Engineering from the Technical University of Denmark (DTU), MSc in Management and Economics from the University of London, and a Fellow of the London Business School Sloan Program
Background: Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.
Other ongoing assignments: CEO of Fertilizer Invest ApS.
Independence: Independent in relation to both the Company and executive management as well as larger shareholders.
Scandion Oncology shares and warrants
28,182 shares and 26,792 warrants
Martin Møller
Member of the Board of Directors since May 2021
Education: MA in comparative literature
Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.
Other ongoing assignments: Board member in Immunovia AB
Independence: Independent in relation to both the Company and executive management as well as larger shareholders
Scandion Oncology shares and warrants
4,700 shares
Bo Rode Hansen
President & CEO and member of the Board of Directors since May 2020
Education: MSc, PhD, MBA
Background: Previously, President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris Pharma (acquired by Roche).
Other ongoing assignments: Advisor for Novo Seeds
Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.
Scandion Oncology shares and warrants
42,442 shares and 1,071,688 warrants
Annie Rasmussen
Member of the Board of Directors (employee representative) since 2020
Education: RN, Master of Public Health
Background: Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982.
Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operations Oncology Venture A/S. Founder of Health- CreationDK and CancerGuidesDK.
Other ongoing assignments: Board member of North Star Group A/S.
Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.
Scandion Oncology shares and warrants
20,000 shares and 53,585 warrants
